To look for associations between the gut microbiome composition and development of Type 2 Diabetes, CMIT collaborated with researchers at institutes and hospitals within Mexico to study a cohort that had not been been diagnosed with, or treated for T2D, avoiding the potential influences of medication and lifestyle changes on gut microbes.
The Center for Microbiome Informatics and Therapeutics was founded to accelerate the development of therapeutics to treat microbiome-associated disease, with a core focus on Inflammatory Bowel Disease (IBD).
In a recently published paper in Nature, Lloyd-Price (et.al) provide a comprehensive analysis of the longitudinal variation in the gut microbiome of patients with IBD.
CMIT is collaborating with Dr. Patricia Pringle and Dr. Raymond Chung from Massachusetts General Hospital (MGH) on a new study that is investigating the potential role of fecal microbiota transplantation (FMT) as a treatment for hepatic encephalopathy.
Dr. Jessica Allegretti is an inspiring example of a clinician who works passionately to improve the lives of those suffering from Inflammatory Bowel Disease (IBD).
The Broad Institute and OpenBiome Microbiome Library (BIO-ML) now supplies a comprehensive collection of nearly 8,000 intestinal bacterial isolates, paired with nearly 4,000 genome sequences, to serve as an open access investigational resource.
The practice of “dropping in” on another country to take whatever is needed to further research, termed “parachute science,” can apply to any scientific field.